Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SMP-028 in inhaled allergen challenge in mild to moderate asthma
2009-012675-10Phase 2Completed
- Sponsor
- Sumitomo Pharma
- Start
- Aug 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of SMP-028 in asthma and allergic rhinitis (AR) (2 arms), sponsored by Sumitomo Pharma. Primary endpoint: Late asthmatic response FEV1 AUC4-10h. Started Aug 2009; status: completed.
02
Drugs
SMP-028
03
Conditions
asthmaallergic rhinitis (AR)
Beyond the preview
Go deeper on 2009-012675-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012675-10.